Long-Term Effectiveness and Safety of Direct Oral Anticoagulants in Japanese Patients With Venous Thromboembolism ― Extended Follow-up Results From the KUROSIO Study ―
Abstract
BACKGROUND: The KUROSIO study (UMIN000023747) previously demonstrated the efficacy and safety of direct oral anticoagulants (DOACs) over 52 weeks in patients with acute venous thromboembolism (VTE). However, the long-term outcomes of anticoagulation therapy in real-world practice remain unclear. METHODS AND RESULTS: We conducted a prespecified analysis with a 156-week clinical observation period. The primary efficacy outcome was symptomatic recurrent VTE, and the primary safety outcome was major bleeding at 156 weeks. Between September 2016 and November 2018, the study enrolled 1,017 patients, of whom 993 were eligible for analysis. The cumulative incidence of recurrent VTE and major bleeding at 52 weeks was 3.2% and 2.2%, respectively. The mean duration of DOAC therapy was 458.0 days. Symptomatic recurrent VTE occurred in 50 (5.0%) patients, including pulmonary embolism in 46 (4.6%) and deep vein thrombosis in 4 (0.4%). Major bleeding occurred in 26 (2.6%) patients. Multivariable analysis identified chemotherapy (hazard ratio [HR] 3.580) as a factor associated with recurrent VTE. For major bleeding, multivariable analysis identified lower baseline hemoglobin (HR 0.657), history of cerebral infarction (HR 7.250), and concomitant use of non-steroidal anti-inflammatory drugs other than aspirin at enrollment (HR 7.481) as significant risk factors. CONCLUSIONS: DOAC therapy showed sustained effectiveness and acceptable safety over 156 weeks in Japanese patients with VTE, supporting individualized decisions regarding treatment duration and bleeding risk.
Related
- CO090 | DIRECT ORAL ANTICOAGULANTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE INHERITED THROMBOPHILIA: A REAL-WORLD MULTICENTER STUDY
- PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
- Real-world comparative effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation
- Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants
- Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
BibTeX
@article{umetsu2026longterm,
title = {{Long-Term Effectiveness and Safety of Direct Oral Anticoagulants in Japanese Patients With Venous Thromboembolism ― Extended Follow-up Results From the KUROSIO Study ―}},
author = {Michihisa Umetsu and Kenichi Tsujita and Masato Nakamura and Atsuyuki Watanabe and Mitsuru Yuzaki and Masataka Sata and Kazuhiko Yumoto and Wataru Shimizu and Koji Maemura and Yoshito Ogihara and Yuki Nishimura and Toru Ogura and Takeshi Yamamoto and Hirono Satokawa and Toru Obayashi and Satoshi Tamaru and Norikazu Yamada and Mashio Nakamura and for the KUROSIO Study Investigators},
journal = {Circulation Journal},
year = {2026},
month = sep,
doi = {10.1253/circj.cj-26-0316},
url = {https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-26-0316/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Long-Term Effectiveness and Safety of Direct Oral Anticoagulants in Japanese Patients With Venous Thromboembolism ― Extended Follow-up Results From the KUROSIO Study ―
AU - Michihisa Umetsu
AU - Kenichi Tsujita
AU - Masato Nakamura
AU - Atsuyuki Watanabe
AU - Mitsuru Yuzaki
AU - Masataka Sata
AU - Kazuhiko Yumoto
AU - Wataru Shimizu
AU - Koji Maemura
AU - Yoshito Ogihara
AU - Yuki Nishimura
AU - Toru Ogura
AU - Takeshi Yamamoto
AU - Hirono Satokawa
AU - Toru Obayashi
AU - Satoshi Tamaru
AU - Norikazu Yamada
AU - Mashio Nakamura
AU - for the KUROSIO Study Investigators
PY - 2026
DA - 2026/09/25
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0316
UR - https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-26-0316/_article
AB - BACKGROUND: The KUROSIO study (UMIN000023747) previously demonstrated the efficacy and safety of direct oral anticoagulants (DOACs) over 52 weeks in patients with acute venous thromboembolism (VTE). However, the long-term outcomes of anticoagulation therapy in real-world practice remain unclear. METHODS AND RESULTS: We conducted a prespecified analysis with a 156-week clinical observation period. The primary efficacy outcome was symptomatic recurrent VTE, and the primary safety outcome was major bleeding at 156 weeks. Between September 2016 and November 2018, the study enrolled 1,017 patients, of whom 993 were eligible for analysis. The cumulative incidence of recurrent VTE and major bleeding at 52 weeks was 3.2% and 2.2%, respectively. The mean duration of DOAC therapy was 458.0 days. Symptomatic recurrent VTE occurred in 50 (5.0%) patients, including pulmonary embolism in 46 (4.6%) and deep vein thrombosis in 4 (0.4%). Major bleeding occurred in 26 (2.6%) patients. Multivariable analysis identified chemotherapy (hazard ratio [HR] 3.580) as a factor associated with recurrent VTE. For major bleeding, multivariable analysis identified lower baseline hemoglobin (HR 0.657), history of cerebral infarction (HR 7.250), and concomitant use of non-steroidal anti-inflammatory drugs other than aspirin at enrollment (HR 7.481) as significant risk factors. CONCLUSIONS: DOAC therapy showed sustained effectiveness and acceptable safety over 156 weeks in Japanese patients with VTE, supporting individualized decisions regarding treatment duration and bleeding risk.
SN - 1347-4820
SN - 1346-9843
ER -